Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Goto, Kōichi; Goto, Yasushi; Kubo, Toshio; Ninomiya, Kiichiro; Kim, Sang‐We; Planchard, David; Ahn, Myung‐Ju; F. Smit, Egbert; J. de Langen, Adrianus; Pérol, M.; Pons‐Tostivint, Elvire; Novello, Silvia; Hayashi, Hidetoshi; Shimizu, Junichi; Kim, Dong‐Wan; S. Kuo, Chih‐Hsi; Chih‐Hsin Yang, James; Pereira, Kaline; Cheng, Fu-Chih; Taguchi, Ayumi; Cheng, Yingkai; Feng, Wenqin; Tsuchihashi, Zenta; A. Jänne, Pasi

doi:10.1200/jco.23.01361

Public

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Published in Journal of Clinical Oncology • Sep 11, 2023

Authors:

Kōichi Goto

Yasushi Goto

Toshio Kubo

Abstract

PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant ( HER2m; defined as single-nucleotide variants...

Subject

Medicine

Internal medicine

Trastuzumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!